Spread to the Peritoneum
The peritoneum is the thin lining inside the abdomen and around many abdominal organs. If cancer spreads there, the next steps depend on where the cancer began, how much of the abdomen is involved, whether cancer is anywhere else, symptoms, tumor biology, overall health and treatments already received.
The peritoneum is a place—not a new kind of cancer.
If colorectal, ovarian, appendix, stomach or another cancer spreads to the peritoneum, it is still the cancer where it began. You may also hear words such as peritoneal metastases or peritoneal disease. The original cancer still matters because it guides systemic treatment and helps determine which specialized approaches may be worth discussing.
Three things can change the conversation.
How much is involved?
The amount and distribution of cancer across the abdominal lining can matter greatly. Specialists may use imaging, surgery and sometimes a score such as the Peritoneal Cancer Index to describe the pattern.
Is cancer anywhere else?
Disease limited to the peritoneum can create a different treatment conversation than cancer that is also widespread outside the abdomen.
What cancer are we treating?
The cancer of origin and its biomarkers remain central. The same abdominal location can call for very different treatment depending on where the cancer began.
Some abdominal symptoms should not wait.
Severe or rapidly worsening abdominal pain, repeated vomiting, a swollen abdomen with inability to pass stool or gas, fever with significant abdominal symptoms, fainting, or sudden severe weakness can require urgent evaluation. Bowel obstruction and other complications can become emergencies.
Treatment may have more than one job.
Treat the cancer throughout the body
Systemic treatment may include chemotherapy, targeted therapy, immunotherapy or other cancer-specific treatment based on where the cancer began, its biomarkers and prior therapy.
Ask whether treatment inside the abdomen belongs in the conversation
For carefully selected patients with certain cancers, specialized surgery—and in some settings treatment delivered directly into the abdominal cavity—may be discussed at experienced centers.
Specialized experience matters here.
Peritoneal disease can be complicated. A multidisciplinary team can help determine whether the goal is systemic control, symptom relief, complete surgical removal in a selected setting, a clinical trial—or a combination.
Medical Oncology
Connects the original cancer, biomarkers, prior treatment and disease everywhere in the body into the systemic plan.
Peritoneal Surface / Surgical Oncology
A surgeon experienced in peritoneal surface cancers can assess the pattern of disease, whether complete cytoreduction may be feasible and whether the potential benefits justify a major operation.
Intraperitoneal Treatment
HIPEC is heated chemotherapy placed into the abdominal cavity during surgery after visible tumor has been removed. Whether it helps depends on the cancer type, drug and clinical setting; it should not be treated as one universal answer for all peritoneal disease.
Supportive / Palliative Care
Peritoneal disease can cause pain, fluid buildup, bowel problems, appetite changes and fatigue. Supportive care can work alongside active treatment to help manage these problems.
Radiation Oncology
When one or a few peritoneal tumors are well defined, highly focused radiation such as SBRT may sometimes be considered for local control—particularly when surgery is not the best fit. Evidence is still developing, so selection and experienced planning matter.
They are related—but they are not the same treatment.
CRS, or cytoreductive surgery, is an operation intended to remove visible cancer from the abdominal cavity. HIPEC is heated chemotherapy circulated inside the abdomen during surgery. Evidence and recommendations differ by the cancer that spread to the peritoneum, so the two should not automatically be bundled together in every conversation.
Current ASCO guidance says cytoreductive surgery plus systemic chemotherapy may be recommended for carefully selected patients with colorectal cancer limited to the peritoneum when complete removal is feasible at a specialized center. The guideline does not recommend adding oxaliplatin-based HIPEC to CRS for colorectal peritoneal metastases. That is exactly why specialist review matters.
Use the RoadMap as your guide.
Ask where the cancer began, how extensive the peritoneal disease is, whether cancer is present outside the abdomen, whether complete surgical removal appears possible, and whether your scans have been reviewed at a center experienced in peritoneal surface cancers. Selection matters. Experience matters. The original cancer matters.
You are allowed to ask “What else?”
A complicated word should not keep you from asking simple questions.
Where is it? How much is there? Can it all be removed? What treatment fits the cancer I actually have? And who else should look at this with us? Those questions can turn “peritoneal disease” from a frightening phrase into a RoadMap you can begin to understand.